Goldman Sachs maintained its St. Jude Medical STJ Neutral rating and $38 price target in a research report published today.
In the report, Goldman Sachs states, "Since the company introduced late stage pipeline details (February 2011), there have been two clinical failures (US Deep Brain Stimulation trial missing primary end-point and negative CardioMEMS panel). That said, new products could be a source of upside."
Shares of St. Jude Medical closed today at $40.30, up 4.51% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in